Abstract
Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 359-371 |
| Number of pages | 13 |
| Journal | Expert Review of Clinical Pharmacology |
| Volume | 2 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2009 |
| Externally published | Yes |
Fingerprint
Keywords
- Clinical trials
- Crystalline glucosamine sulfate
- Glucosamine hydrochloride
- Knee osteoarthritis
- Osteoarthritis
- Osteoarthritis therapy
- Pharmacokinetics
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Glucosamine therapy for knee osteoarthritis : Pharmacokinetic considerations. / Altman, Roy D.
In: Expert Review of Clinical Pharmacology, Vol. 2, No. 4, 2009, p. 359-371.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Glucosamine therapy for knee osteoarthritis
T2 - Pharmacokinetic considerations
AU - Altman, Roy D
PY - 2009
Y1 - 2009
N2 - Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.
AB - Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.
KW - Clinical trials
KW - Crystalline glucosamine sulfate
KW - Glucosamine hydrochloride
KW - Knee osteoarthritis
KW - Osteoarthritis
KW - Osteoarthritis therapy
KW - Pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=70149088596&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70149088596&partnerID=8YFLogxK
U2 - 10.1586/ecp.09.17
DO - 10.1586/ecp.09.17
M3 - Article
C2 - 22112180
AN - SCOPUS:70149088596
VL - 2
SP - 359
EP - 371
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
SN - 1751-2433
IS - 4
ER -